Objective: Inhaled nitric oxide (NO) is used as a therapy of pulmonary hypertension in children after cardiac surgery. Hemoglobin binds to NO with great affinity and forms methemoglobin by oxidation in the erythrocyte. Once produced, methemoglobin is unable to transport and unload oxygen in the tissues. The amount of available hemoglobin in the body for oxygen transport is thereby reduced. Anemia, acidosis, respiratory compromise and cardiac disease may render patients more susceptible than expected for a given methemoglobin level. The goal of the present study was to review the cumulative effect of inhaled NO on methemoglobin formation in critically ill children. We therefore looked for methemoglobin levels in children with congenital heart disease after cardiac surgery who were treated with inhaled NO in a range of 5-40 ppm. Methods: We retrospectively reviewed the medical charts of 38 children with congenital heart disease after cardiac surgery. We extracted demographic data and physiological measurements at the following time points: (1) T0 = before starting inhaled NO therapy, (2) T1 = 24 h after the beginning of inhaled NO therapy, (3) T2 = half-time therapy, (4) T3 = end of therapy, (5) T4 = 24 h after finishing inhaled NO therapy. Results: The median duration of inhaled NO therapy was 5.5 days (interquartile range 6, range 2-29), NO concentrations at T1 and T2 Keywords Inhaled nitric oxide · Methemoglobin · Congenital heart disease · Pulmonary hypertension ·
were 16 ppm (10, 5-40) and 12.5 ppm (12.3, 2-40), respectively. The median cumulative dose of inhaled NO was 1699 ppm (2313, . Methemoglobin levels increased moderately, but significantly, during therapy ( T0 vs T1 p<0.05 and T0 vs T2 p<0.001). The highest methemoglobin level measured was 3.9%. Methemoglobin levels correlated positively with the inhaled NO doses applied at T1 (r 2 =0.8376; p<0.01) and at T2 (r 2 =0.8945; p<0.01). At T1 the methemoglobin level correlated negatively with the T1 blood pH value. The overall mortality rate was 13.2% (5 of 38 study patients died). There was no significant difference in methemoglobin levels between survivors and non-survivors. Conclusion: We conclude from our data that the use of inhaled NO therapy for children with congenital heart disease after cardiac surgery in the described range of 5-40 ppm, resulting in a maximum of 4% methemoglobin blood level, is feasible and safe. However, we recommend the use of the minimal effective dose of inhaled NO and continuous monitoring of methemoglobin levels, especially in cases of anemia or sepsis in critically ill children.
Introduction
Congenital heart disease (CHD) increases pulmonary blood flow or causes pulmonary venous obstruction and thereby may produce pulmonary artery smooth muscle hypertrophy, hyperplasia leading to pulmonary vasoconstriction. This pulmonary vasoconstriction can persist and progress to vascular obliteration that usually leads to pulmonary hypertension. This condition is associated with high morbidity unless surgical correction of the underlying congenital heart lesion has been performed.
In children with CHD, pulmonary hypertension remains a problem in the postoperative period of cardiac surgery, especially when cardiopulmonary bypass was used or when only palliative surgery was performed. Inhaled nitric oxide (NO) has been increasingly used in the therapy of pulmonary hypertension after cardiac surgery [1, 2, 3] , but it has not yet been licensed here as it has been in other etiologies of pulmonary hypertension, such as persistent pulmonary hypertension of the newborn (PPHN) [4, 5, 6] . Inhaled NO is a powerful selective vasodilating agent acting in the pulmonary vascular bed. NO diffuses into the intravascular space, where it is rapidly bound to hemoglobin and inactivated [7] .
However, Frostell et al. [8] postulated that NO oxidizes hemoglobin to methemoglobin. It is known that, in critically ill patients (who may not have normal oxygen saturation), deoxyhemoglobin is more likely to form methemoglobin than oxyhemoglobin [9] . This may reduce oxygencarrying capacity and hence delivery to the tissue in the case of increased formation of methemoglobin. Although no optimal dosing recommendations for inhaled NO have yet been reported, most studies give the impression that there is no difference between 2 and 20 ppm. Kinsella and Abman [10] suggested 20 ppm as a reasonable starting dose for term infants, followed by stepwise reductions over time. They also mentioned that methemoglobin toxicity becomes apparent at 80 ppm of inhaled NO.
The goal of the present study was to review the cumulative effect of inhaled NO on methemoglobin formation by measuring methemoglobin blood levels in children with CHD after cardiac surgery. These children were treated with inhaled NO in a range of 5-40 ppm over a time period of 2-29 days.
Methods

Study population
We conducted a retrospective chart review study between 1998 and 1999 on 38 children with CHD. All 38 children were treated postoperatively after cardiac surgery on cardiopulmonary bypass with inhaled NO. Inhaled NO therapy was initiated only when conventional management (e.g. 100% oxygen with manual hyperventilation, deepening the level of anesthesia) of pulmonary hypertension had failed. We retrospectively reviewed all children with CHD who developed severe pulmonary hypertension (when mean pulmonary artery pressure (PAP) was 50% or more of the mean systemic arterial pressure) within the first 5 days after cardiac surgery. We examined each patient's medical chart for demographic data and physiological measurements. Patients who received nitroso-compounds such as nitroglycerin or nitroprusside or were exposed to aniline dyes or any other oxidizing medication were not included in the study. Informed consent and approval by the hospital ethics committee were not necessary, because the study was a retrospective data analysis.
The diagnosis of pulmonary hypertension was made by two-dimensional m-mode and Doppler echocardiographic studies with a Sonos 2500 system (Hewlett-Packard , Palo Alto, CA, USA) by means of a 5 MHz transducer. The diagnosis was based on standard echocardiographic criteria [11] . Some of the study patients had a pulmonary artery catheter with online monitoring of PAP.
Monitoring and therapy device Each patient was monitored by pulse oximetry, a 3-lead electrocardiogram and had a radial or femoral artery line and a central venous catheter. Hemodynamic data were continuously monitored on a Hewlett-Packard monitoring system (Model 68 S Hewlett-Packard, Palo Alto, CA, USA). All children received at least midazolam and fentanyl or pethidine hydrochloride analgesia administered by continuous infusion and were paralyzed with pancuronium bromide. The patients were ventilated with Baby-log 8000 or with EVITA 2 conventional ventilators (Dräger, Lübeck, Germany). NO was delivered by a Pulmonox Mini (Messer Griesheim, Gumpoldskirchen, Austria) system. Inspiratory concentrations of inhaled NO were continuously monitored with this system. All children in the study were treated with a starting dose of 5-40 ppm. This dose was reduced according to the clinical course of pulmonary hypertension.
Twenty-four hours before starting to wean the patients from inhaled NO the children received intravenous prostacyclin (5-20 ng/kg per min) to mitigate possible rebound effects after NO withdrawal [12] .
Measurements
From each of the 38 patients demographic and specific medical data (blood gas, methemoglobin level, ventilator settings, vital parameters) were extracted from the medical records at the following times: (1) T0 = before starting inhaled NO therapy, (2) T1 =24 h after starting inhaled NO therapy, (3) T2 = half-time of inhaled NO therapy, (4) T3 = at the end of therapy, (5) T4 =24 h after finishing inhaled NO therapy. Blood gas analysis and methemoglobin levels were measured with an ABL 700 analyzer (Radiometer Copenhagen, Denmark). This blood gas analyzer provides accurate methemoglobin measurements (error <0.2%). All methemoglobin levels were measured with the same analyzer within the study period to eliminate potential variability over the time of measurements. Methemoglobin values are expressed as the percentage of total hemoglobin. For each study patient we calculated the "cumulative parts per million doses of inhaled NO" with the following formula:
Data analysis
All data are presented as medians, interquartile range and range unless otherwise specified. Statistical analysis was performed by using one-way ANOVA (Friedman Test or Kruskal Wallis Test + Dunn's post hoc test) and a Pearson correlation between parameters. A p value of less than 0.05 was considered to indicate significance. Statistical analysis was performed by using statistical programs SPSS (SPSS, Chicago IL, USA) and Prism for PC version (GraphPad Software, USA).
Results
Between 1998 and 1999, 693 children were admitted to our PICU. From those 693 children, 343 (49.5%) children had CHD. Of these children, 121 (17.5%) were treated with inhaled NO. Thirty-eight children who had CHD and were treated postoperatively with inhaled NO (5.5% of all admissions and 33.4% of all children treated with inhaled NO) were retrospectively reviewed.
Each study patient had echocardiographic evidence of pulmonary hypertension [11] despite aggressive treatment with hyperventilation and inspired oxygen levels of 100%. The median age of all 38 patients was 3 months (interquartile range 5.7 and range 1-72) and median weight was 4.6 kg (2.3, 2.8-21). The duration of mechanical ventilation was 12.5 days (14.5, 4-41). The median hospital and PICU stays were 32.5 days (19.3, 12-175) and 15.5 days (14.7, 5-47), respectively. The duration of inhaled NO therapy was 5.5 days (6, 2-29) or 125 h (135.8, 43-705). Measurements of NO concentration during therapy (T1 and T2) at the inspiratory limb of the respiratory system showed, for T1, 16 ppm (10, 5-40) and, for T2, 12.5 ppm (12.3, 2-40) with no significant differences between the two time points. The median cumulative dose of inhaled NO was 1699 ppm (2313, 193-7018). The methemoglobin, hemoglobin, lactate dehydrogenase and CRP levels between T0 and T4 are list-ed in Table 1 . The demographic data according to diagnosis are listed in Table 2 .
Methemoglobin levels increased significantly during inhaled NO therapy (T0 vs T1 p<0.05 and T0 vs T2 p<0.001), see also Fig. 1 . Comparison of methemoglobin levels during therapy showed significant differences: T1 vs T3 (p<0.05), T1 vs T4 (p<0.001) T2 vs T3 and T4 (p<0.001). The highest methemoglobin level measured was 3.9%. Methemoglobin levels correlated positively with the inhaled NO ppm doses applied at T1 (r 2 =0.8376; p<0.01) and at T2 (r 2 =0.8945; p<0.01) ( Figs. 2 and 3) . At T1 the methemoglobin level was negatively correlated with the T1 blood pH value. However, no significant correlation was found between methemo-449 Fig. 1 Methemoglobin levels at the following set points during the study period: T0 = before starting inhaled nitric oxide (NO) therapy, T1 =24 h after starting inhaled NO therapy, T2 = halftime of inhaled NO therapy, T3 = at the end of inhaled NO therapy, T4 =24 h after finishing therapy. Comparing methemoglobin levels between the different time points of therapy showed a significant difference: † = T0 vs T1 (p<0.05), * = T0 vs T2 (p<0.001) and T2 vs T3 and T4 (p<0.001) globin levels and the duration of inhaled NO therapy, or between methemoglobin levels and hemoglobin, lactate or CRP levels.
Five out of 38 children died (13.2%). Six children (15.8%) needed extracorporeal membrane oxygenation (ECMO) support after cardiac surgery. Neurologic outcome was divided in four categories: 1=normal, 2=moderately handicapped, 3=severely handicapped and 4=died. Twenty children (52.6%) were normal, 3 (7.9%) children presented a moderate handicap and, 10 (26.3%) children were severely handicapped. These outcome data were related to neither cumulative inhaled NO dose or methemoglobin levels, nor the duration of inhaled NO therapy. There was no significant difference in methemoglobin levels between survivors and non-survivors.
Discussion
In this retrospective chart review study we looked for the effect of inhaled NO on methemoglobin formation in children with CHD after cardiac surgery. This study extends the findings of previous reports [2, 3] that methemoglobin levels in children with CHD after cardiac surgery treated with inhaled NO did not cause toxic adverse effects. We found that methemoglobin levels increased significantly (see Table 1 and Fig. 1 ) during inhaled NO therapy (T0 vs T1 and T2, p<0.01) although doses were reduced between these time points, but did not reach toxic levels. The highest single methemoglobin level of one of the patients during therapy was 3.9%. Between the end of therapy (T3) and 24 h later (T4) methemoglobin . There was a significant correlation (r 2 =0.8945; p<0.01) between the two variables levels decreased significantly and returned to normal blood levels (see Table 1 and Fig. 1 ). Dötsch et al. [13] have shown that children after cardiac surgery, especially when cardiopulmonary bypass was used, have a high risk of increased methemoglobin formation during inhaled NO therapy. This risk of methemoglobinemia appears to be greatest during the first postoperative hours and in combination with a dose above 20 ppm of inhaled NO (after application of 80 ppm, 5 of 25 children had methemoglobin levels >5%). The reason for this increased methemoglobin concentration might be an impaired reduction of methemoglobin to hemoglobin in the red blood cell after cardiopulmonary bypass. This impairment could be due to either a lack of energetic substrates for the different methemoglobin-reducing enzymes or reduced activity of the enzymes themselves [14] . However, Dötsch and his colleagues were unable to define the exact mechanism responsible for the increased methemoglobin formation by inhaled NO after cardiopulmonary bypass.
In 1993 Kinsella et al. [15] measured methemoglobin levels in nine children with PPHN 4 h after starting inhaled NO therapy and observed a significant increase from a baseline level of 0.87%±0.03% to 1.44%±0.09%. They also observed a fall in methemoglobin levels after reduction of the inhaled NO concentration. However, they reported that methemoglobin levels at the 24-h time point did not differ from baseline (0.98%±0.07%). In our patients we found a significant increase of methemoglobin levels between T0 (baseline) and T1 (24-h time point) and even T2 (half-time of therapy) as shown in Table 1 .
Several studies have shown that methemoglobin levels during inhaled NO therapy remained low (between 0.8% and 1.5% during mechanical ventilation). This is because of the short-term exposures to NO and a constant reduction of methemoglobin by an erythrocyte methemoglobin-reductase back to hemoglobin [15, 16, 17, 18, 19, 20] . Although higher methemoglobin levels (from 7% to 17%) have been reported in some studies [21, 22] no adverse clinical effects were seen.
Regardless of the etiology, the severity of symptoms depends on the methemoglobin level. Cyanosis caused by methemoglobin becomes clinically apparent at a methemoglobin level of 1.5 g/dl. In a normal healthy person, this is usually about 15% of total hemoglobin. Levels above 70% may cause death. An anemic patient may present more pronounced symptoms at a level of 20% than a non-anemic patient, because the oxygen-carrying capacity is already lower and, therefore, more easily compromised. Anemia, acidosis, respiratory compromise and cardiac disease may also render patients more susceptible than expected for a given methemoglobin level [23] . Although we did not find methemoglobin levels above the toxic range reported, we agree with Ohashi et al. [24] who recommended the use of the minimum effective dose of inhaled NO together with frequent measurements of methemoglobin levels, especially in the postoperative period, where bleeding can cause transient anemia, or when sepsis is suspected. However our patients had no signs of anemia or sepsis.
From our data we conclude that the long-term use of inhaled NO therapy for children with CHD after cardiac surgery in the described range of 5-40 ppm, resulting in a maximum of 4% methemoglobin blood level, is feasible and safe. We are well aware that retrospective studies are not the optimal instrument with which to evaluate safety, but they can be used to generate hypotheses for prospective controlled studies in the future, which may prove and define exact indications and dosing recommendations for the safe use of inhaled NO in critically ill children.
